Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here.

Drugs - 1 Apr 2026

May Michael S, Park Wungki, O'Reilly Eileen M

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and is a rising cause of morbidity and mortality. An immunosuppressive, hostile tumor microenvironment, and KRAS-driven biology have contributed to poor outcomes in PDAC. Recent breakthroughs in targeting tumors with homologous repair deficiency, KRASG12C mutations, rare gene fusions, and other molecular abnormalities have improved...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cancer Vaccines
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41731281
DOI: 10.1007/s40265-026-02295-0
PMCID: PMC13005833

Genes

KRAS
PRMT5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here.PMID 41731281Read ↗

Emerging Treatment Strategies in Pancreatic Cancer.Semantic proximity Read ↗

Targeted Therapies in Pancreatic Cancer: A New Era of Precision MedicineSemantic proximity Read ↗

Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.Semantic proximity Read ↗

Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)Semantic proximity Read ↗

New therapeutic targets in pancreatic cancer.Semantic proximity Read ↗

A Young Scientist's Guide to PDAC: Past, Present, and FutureSemantic proximity Read ↗

Moving the Needle on Precision Medicine in Pancreatic CancerSemantic proximity Read ↗

Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.Semantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Semantic proximity Read ↗

Personalized Medicine in Pancreatic Cancer: The Promise of Biomarkers and Molecular Targeting with Dr. Michael J. PishvaianSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.